• Thursday, June 10, 2021 @ 12:00 am

  • The new establishment is part of Tillotts ambitious expansion plans throughout Europe
  • The Swiss sales team will focus on meeting the needs of healthcare professionals offering service, support and an innovative portfolio
  • YaldigoTM 1600 mg (mesalazine) will be the next product to launch, recently acquired product DificlirTM (fidaxomicin) expected to drive sustainable growth for the company

Tillotts Pharma AG ("Tillotts"), part of the Japanese Zeria Group, today announced its new sales organisation in Switzerland. After having its headquarter for more than 35 years in Switzerland, the gastrointestinal (GI) specialist starts now actively promoting its products. The launch of Yaldigo 1600 mg, the highest strength mesalazine tablet currently available on the market, and the recently acquired Dificlir are expected to boost Tillotts Switzerland sales.

Today Tillotts operates in 65 countries through its own affiliates and distributors. Over the last decade, the company built, through a combination of organic growth and various product acquisitions, a strong portfolio in the field of GI diseases and extended its presence in strategic markets. “We are very proud to be able to strengthen our sales efforts in the Swiss home market now also. Establishing a Swiss sales organisation reflects our aspiring growth strategy for the coming years to extend our presence throughout Europe and beyond,” says Thomas A. Tóth von Kiskér, CEO of Tillotts Pharma. Prior to the Swiss opening, Tillotts recently started its activities in Belgium, the Netherlands and Luxembourg shaping its European network.

Tillotts is aiming to concentrate on the further commercialisation of existing products such as Entocort (budesonide), a first-line treatment indicated for mild to moderate Crohn’s disease and microscopic colitis as well as for ulcerative colitis (UC) and Colpermin, a treatment for the symptoms of Irritable Bowel Syndrome such as painful cramps and bloating. Furthermore, the launch of Yaldigo 1600 mg and the integration of Dificlir will enhance the portfolio on the Swiss market and lay the path in offering healthcare professionals innovative treatment solutions. Yaldigo 1600 mg is indicated for the induction and maintenance of mild to moderate UC, whereas Dificlir, a narrow-spectrum antibiotic, will fill a gap in the treatment of patients suffering from Clostridoides difficile infections (CDI).

“Investing in marketing and medical activities in Switzerland represents an exciting new chapter for the company and stresses our commitment to explore commercial growth opportunities in core markets and offer localised services,” says Mattias Norrman, Chief Operations Officer at Tillotts. “The launch of Yaldigo 1600 mg enhances our strong product portfolio for the digestive system and will help to address the unmet treatment needs for patients living with ulcerative colitis”, he further explains.